.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
US Department of Justice
Accenture
Cerilliant
Baxter
Novartis
Medtronic
Teva
Express Scripts

Generated: December 15, 2017

DrugPatentWatch Database Preview

ENLON-PLUS Drug Profile

« Back to Dashboard

When do Enlon-plus patents expire, and when can generic versions of Enlon-plus launch?

Enlon-plus is a drug marketed by Mylan Institutional and is included in two NDAs.

The generic ingredient in ENLON-PLUS is atropine sulfate; edrophonium chloride. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atropine sulfate; edrophonium chloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Mylan InstitutionalENLON-PLUSatropine sulfate; edrophonium chlorideINJECTABLE;INJECTION019677-001Nov 6, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Mylan InstitutionalENLON-PLUSatropine sulfate; edrophonium chlorideINJECTABLE;INJECTION019678-001Nov 6, 1991RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ENLON-PLUS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan InstitutionalENLON-PLUSatropine sulfate; edrophonium chlorideINJECTABLE;INJECTION019677-001Nov 6, 1991► Subscribe► Subscribe
Mylan InstitutionalENLON-PLUSatropine sulfate; edrophonium chlorideINJECTABLE;INJECTION019678-001Nov 6, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Chinese Patent Office
Accenture
Julphar
McKinsey
Cipla
US Department of Justice
Queensland Health
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot